

Forschungsprojekte 2021 (1. Semester)

Projets de recherche 2021 (1^{er} semestre)

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Grundlagenforschung / Recherche fondamentale			
<u>Gesuchsteller/In</u>	<u>Projektnummer</u> <u>Projekttitel</u>	<u>Dauer</u> <u>(Monate)</u>	<u>Betrag</u> <u>(CHF)</u>
<u>Candidat/e</u>	<u>Numéro du projet</u> <u>Titre du projet</u>	<u>Durée</u> <u>(mois)</u>	<u>Montant</u> <u>(CHF)</u>
Alimonti Andrea , Prof. Dr med. Istituto oncologico della Svizzera italiana (IOSI), Istituto Oncologico di Ricerca (IOR) 6500 Bellinzona	KFS 5262-02-2021 Reverting prostate cancer immunosuppression by hijacking cellular senescence	36	257 700.–
Bachmann Martin , Prof. Dr. Department for BioMedical Research (DBMR), University of Bern 3010 Bern	KFS 5246-02-2021 Intratumour immunotherapy using TLR7/8 loaded nanoparticles formulated with an inflammasome activating micron-sized particulate adjuvant (MCT) in solid murine tumour models	36	371 350.–
Chijioke Obinna , Dr. Institute of Experimental Immunology University of Zurich 8057 Zurich	KFS 5292-02-2021 Novel autologous humanized tumour models and their use in target discovery for engineering cellular immunotherapy	36	372 000.–
Coppari Roberto , Prof. Cell Physiology and Metabolism University of Geneva 1211 Geneva	KFS 5253-02-2021 To determine the role of FKBP10 in colorectal cancer	36	375 000.–
Hall Michael N. , Prof. Dr. Biochemistry University of Basel 4056 Basel	KFS 5281-02-2021 Selective mTORC1 inhibition as an innovative anti-cancer approach	18	187 500.–
Joyce Johanna , Prof. Department of Oncology University of Lausanne 1011 Lausanne	KFS 5280-02-2021 Microenvironmental regulation of therapeutic resistance in glioblastoma	36	361 750.–

<p>Pascolo Steve, PD Dr. Klinik für Dermatologie UniversitätsSpital Zürich (USZ) 8091 Zürich</p>	<p>KFS 5271-02-2021 Enhancing therapy of cancer using immuno- chemotherapeutic RNA nanoparticles and immune check-point inhibition</p>	<p>36</p>	<p>245 450.–</p>
<p>Plückthun Andreas, Prof. Dr. Biochemisches Institut Universität Zürich (UZH) 8057 Zürich</p>	<p>KFS 5290-02-2021 Novel approaches of targeting the RAS subfamily of small GTPases in human cancer</p>	<p>36</p>	<p>344 950.–</p>
<p>Razansky Daniel, Prof. Dr. Institute for Biomedical Engineering University of Zurich 8093 Zurich</p>	<p>KFS 5234-02-2021 Optoacoustic monitoring of radiotherapy response dynamics in murine models of pancreatic cancer for physiological treatment adaptation</p>	<p>24</p>	<p>245 750.–</p>
<p>Tugues Sonia, Dr Institute of Experimental Immunology University of Zurich 8057 Zurich</p>	<p>KFS 5240-02-2021 Innate lymphocyte surveillance of liver metastasis</p>	<p>36</p>	<p>365 450.–</p>
<p>vom Berg Johannes, Dr. Institute of Laboratory Animal Science (LTK) University of Zurich 8952 Schlieren</p>	<p>KFS 5306-02-2021 Elucidating mechanism of action of local, compartment locked immunotherapies in a checkpoint resistant murine brain tumour model and patient derived GB explant culture</p>	<p>36</p>	<p>372 750.–</p>

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bourquin Jean-Pierre Prof. Dr. med. Dr. nat. Abteilung Onkologie Kinderspital Zürich 8032 Zürich	KFS 5298-02-2021 Enhancer factor EP300/CREBBP and metabolic dependencies in high-risk acute lymphoblastic leukaemia	36	375 000.–
Dibner Charna , Prof. Medicine University of Geneva 1211 Geneva	KFS 5266-02-2021 Circadian clockwork and the lung tumourigenesis in humans: underlying mechanisms and new avenues for diagnostics and treatment	36	374 950.–
Jandus Camilla , Dr med. Department of Pathology and Immunology, PATIM University of Geneva 1211 Geneva	KFS 5250-02-2021 Innate lymphoid cell (ILC)-driven immune modulation in ovarian cancer	36	369 600.–
Kurzeder Christian , Dr. Gynaecology and Gynaecologic Oncology University Hospital Basel 4031 Basel	KFS 5245-02-2021 Is axillary dissection necessary to determine the need for chemotherapy in patients with clinically node-positive breast cancer?	42	343 450.–
Läubli Heinz , Prof. Medical Oncology Department of Biomedicine University Hospital Basel 4031 Basel	KFS 5239-02-2021 Targeting fibroblast activation protein in patients with liver metastasis by redirection of T-cells	36	373 900.–
Michelin Olivier , Prof. Medical Oncology Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 5261-02-2021 Digital pathology-based prognostic and predictive biomarker discovery for precision immuno-oncology	36	315 250.–
Müller Anne , Prof. Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich	KFS 5228-02-2021 Identifying and overcoming immune evasion strategies of diffuse large B-cell lymphoma	36	375 000.–
Nardelli Haefliger Denise PD Dr phil. II Service d'urologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 5237-02-2021 Influence of the microbiota on high risk non-muscle invasive bladder cancer and BCG immunotherapy	36	359 450.–

<p>Pauli Chantal, Ass. Prof. Department for Pathology and Molecular Pathology University Hospital Zurich 8006 Zurich</p>	<p>KFS 5270-02-2021 Uncover therapeutic vulnerabilities in cancer of unknown primary (CUP) by using patient- derived tumour organoids (PDTO), in-depth molecular profiling and pharmacotyping</p>	36	339 650.–
<p>Poyet Cédric, PD Dr. med. Klinik für Urologie UniversitätsSpital Zürich (USZ) 8091 Zürich</p>	<p>KFS 5308-02-2021 Towards individualization of bladder cancer therapy: the role of microbiome in BCG responsiveness prediction</p>	42	241 050.–
<p>Pruschy Martin, Prof. Dr. sc. nat. Departement für Radio-Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich</p>	<p>KFS 5301-02-2021 Radioimmunotherapy-treated primary tumours prime secondary tumours to treatment</p>	36	374 650.–
<p>Rossi Davide, Dr Lymphoma & Genomics Research Program Institute of Oncology Research (IOR) 6500 Bellinzona</p>	<p>KFS 5257-02-2021 Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance</p>	36	367 300.–
<p>Rossi Lorenzo, Dr Oncology and Hematology Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona</p>	<p>KFS 5249-02-2021 SIESTA: a pilot study to investigate and evaluate poor sleep quality in cancer patients following hormonal therapeutic approaches: breast cancer survivors receiving endocrine therapy</p>	24	168 400.–
<p>Schwaller Jürg, Prof. Dr. med. Departement Biomedizin DBM Universitäts-Kinderspital beider Basel (UKBB) 4031 Basel</p>	<p>KFS 5267-02-2021 Modelling, mechanisms and targeting of human acute erythroleukaemia</p>	36	371 600.–

Epidemiologische Forschung / Recherche épidémiologie

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Ansari Marc , Prof. Dr Unité d'onco-hématologie pédiatrique Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS 5229-02-2021 RELIVE - International registry for paediatric patients with a relapsed or refractory hepatoblastoma or hepatocellular carcinoma	36	62 100.–
Bonadies Nicolas Prof. Dr. med. Department of Haematology and Central Haematology Laboratory Inselspital Bern 3010 Bern	KFS 5230-02-2021 I-CARE for MDS: impact of guideline adherence on effectiveness and safety of health care provided to MDS patients	48	375 000.–
Katapodi Maria , Prof. Dr. Clinical Research Faculty of Medicine University of Basel 4055 Basel	KFS 5293-02-2021 The CASCADE II study: use of genetic information to guide cancer surveillance for hereditary breast/ovarian cancer and lynch syndrome in Switzerland	36	375 000.–
Kuehni Claudia E. Prof. Dr. med. Institut für Sozial- und Präventivmedizin (ISPM) Universität Bern 3012 Bern	KFS 5302-02-2021 Pulmonary dysfunction after childhood cancer: assessing early stage disease (Phase 2)	36	369 150.–
Petignat Patrick , Prof. Unité d'oncogynécologie chirurgicale Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS 5312-02-2021 Promoting comprehensive cervical cancer prevention and better women's health in low- and medium resource settings	36	373 800.–
Rapiti Elisabetta , Prof. Geneva Cancer Registry University of Geneva 1211 Genève	KFS 5243-02-2021 Importance of microsatellite instability, BRAFV600E mutation and immunoscore on colorectal cancer prognosis: a population- based cohort in Geneva	18	169 350.–

Stipendien 2021 (1. Semester)

Bourses 2021 (1^{er} semestre)

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Pratsinis Manolis , Dr. med. Klinik für Urologie Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	BIL KFS 5248-02-2021 ABCB1 in patients with intermediate and high-risk prostate cancer and DNA repair gene defects treated with a neoadjuvant PARP inhibitor (Niraparib) prior to surgery: assessment of a potential biomarker and correlation with the pathologic response rate Destination: Department of Urologic Surgery, University of California Davis, USA	24	143 500.–